Rapid and flexible batch production of medicines for early clinical trials
| Reference number | |
| Coordinator | Extem Pharma AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | November 2025 - July 2026 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups 2025 |
Important results from the project
Extem Pharma provides services in formulation development and manufacturing of pharmaceutical products for clinical and preclinical studies in both human and veterinary medicine. The objective of establishing the company as a well-known and recognized player has been validated by ongoing discussions with several prospective clients about assignments and quotations. It also became evident that the demand for new, flexible technologies has significant potential across a range of application areas.
Expected long term effects
Developing new business areas enables the company to broaden its customer base and reach additional market segments. This creates opportunities for growth and business expansion. A more diversified customer portfolio reduces dependence on individual customers and sectors, increasing stability and reducing sensitivity to economic fluctuations.
Approach and implementation
The project was carried out through three parallel work packages. The Project Manager coordinated activities and led a team of internal resources and external consultants. To strengthen the company’s market presence, promotional materials, including roll-ups, a logo, an image library, and a communication strategy, were developed. A market analysis based on interviews with customers and partners was conducted, and the company’s value proposition was successfully validated.